The trial missed the primary endpoint of slowing cognitive decline in the overall study population. Topline results were announced from a phase 3 trial evaluating valiltramiprosate (ALZ-801) in ...

Overall, glucose-lowering therapy was not significantly associated with a reduction in all-cause dementia or cognitive impairment. Treatment with glucagon-like peptide-1 receptor agonists (GLP ...